LPTX Stock Overview
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer.
Leap Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.90|
|52 Week High||US$3.77|
|52 Week Low||US$0.85|
|1 Month Change||-39.74%|
|3 Month Change||-25.17%|
|1 Year Change||-74.92%|
|3 Year Change||-24.55%|
|5 Year Change||-83.62%|
|Change since IPO||-88.58%|
Recent News & Updates
Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05
Leap Therapeutics press release (NASDAQ:LPTX): Q2 GAAP EPS of -$0.15 misses by $0.05. Cash and cash equivalents totaled $90.9 million at June 30, 2022, expected to provide financial runway to mid-2024 Shares +1.54% PM.
|LPTX||US Biotechs||US Market|
Return vs Industry: LPTX underperformed the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: LPTX underperformed the US Market which returned -23.2% over the past year.
|LPTX Average Weekly Movement||12.7%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: LPTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: LPTX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd.
Leap Therapeutics Fundamentals Summary
|LPTX fundamental statistics|
Is LPTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LPTX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.50|
|Net Profit Margin||-6,576.93%|
How did LPTX perform over the long term?See historical performance and comparison
Is LPTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LPTX?
Other financial metrics that can be useful for relative valuation.
|What is LPTX's n/a Ratio?|
Price to Book Ratio vs Peers
How does LPTX's PB Ratio compare to its peers?
|LPTX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
ADVM Adverum Biotechnologies
FIXX Homology Medicines
CUE Cue Biopharma
LPTX Leap Therapeutics
Price-To-Book vs Peers: LPTX is expensive based on its Price-To-Book Ratio (1.1x) compared to the peer average (1x).
Price to Earnings Ratio vs Industry
How does LPTX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: LPTX is good value based on its Price-To-Book Ratio (1.1x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is LPTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||1.1x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate LPTX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of LPTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate LPTX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LPTX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Leap Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LPTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LPTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LPTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LPTX is forecast to have no revenue next year.
High Growth Revenue: LPTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LPTX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Leap Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LPTX is currently unprofitable.
Growing Profit Margin: LPTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LPTX is unprofitable, and losses have increased over the past 5 years at a rate of 9.4% per year.
Accelerating Growth: Unable to compare LPTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LPTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: LPTX has a negative Return on Equity (-59.2%), as it is currently unprofitable.
Discover strong past performing companies
How is Leap Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: LPTX's short term assets ($92.4M) exceed its short term liabilities ($10.4M).
Long Term Liabilities: LPTX's short term assets ($92.4M) exceed its long term liabilities ($474.0K).
Debt to Equity History and Analysis
Debt Level: LPTX is debt free.
Reducing Debt: LPTX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LPTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LPTX has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 8.7% each year.
Discover healthy companies
What is Leap Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Leap Therapeutics Dividend Yield vs Market|
|Company (Leap Therapeutics)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Leap Therapeutics)||n/a|
Notable Dividend: Unable to evaluate LPTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LPTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LPTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LPTX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LPTX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Doug Onsi (53 yo)
Mr. Douglas E. Onsi, also known as Doug, J.D., serves as Director at Leap Therapeutics, Inc. since 2020. He serves as Managing Director of HealthCare Ventures LLC. He joined the HealthCare Ventures LLC in...
CEO Compensation Analysis
|Doug Onsi's Compensation vs Leap Therapeutics Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$2m||US$596k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$2m||US$513k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$817k||US$400k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$682k||US$400k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$3m||US$397k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$381k||US$350k|
Compensation vs Market: Doug's total compensation ($USD1.54M) is above average for companies of similar size in the US market ($USD781.86K).
Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.
Experienced Management: LPTX's management team is considered experienced (2.5 years average tenure).
Experienced Board: LPTX's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.5%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Leap Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Leap Therapeutics, Inc.
- Ticker: LPTX
- Exchange: NasdaqGM
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$88.911m
- Shares outstanding: 99.02m
- Website: https://www.leaptx.com
Number of Employees
- Leap Therapeutics, Inc.
- 47 Thorndike Street
- Suite B1-1
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LPTX||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jan 2017|
|5MC1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 2017|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/03 00:00|
|End of Day Share Price||2022/10/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.